At the news
? BULLISHIMPACT 7/10 8-K filed May 29, 2026 at 09:56 ET
Replimune announced it will resubmit its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma, following collaborative discussions with the FDA. The FDA has indicated it will treat the resubmission as an urgent matter and prioritize its review, citing significant unmet need. This is a material regulatory catalyst for a clinical-stage biotech with no approved products, as RP1 is the company's lead asset.
- Replimune will resubmit the RP1 BLA for advanced melanoma in combination with nivolumab in the coming days.
- FDA will treat the BLA resubmission as an urgent matter and prioritize its review.
- Approximately 8,500 Americans with advanced melanoma die each year; standard checkpoint inhibitor therapy fails about half of patients.
- The BLA is supported by data from the IGNYTE clinical trial in patients with confirmed progression on anti-PD-1 therapy.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access